Successful treatment of refractory enteropathy-associated T-cell lymphoma using high-dose chemotherapy and autologous stem cell transplantation.

Abstract

A 65-year-old woman presented with a 6-month history of abdominal pain and watery diarrhea. Type II enteropathy-associated T-cell lymphoma (EATL) was diagnosed based on the clinical presentation and pathological examination of the tumor. The patient received combination chemotherapy but did not achieve remission. Subsequently, high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) were performed. After these therapies, she achieved complete remission, which has been sustained for 18 months. Although the role of HDT-ASCT for EATL is still controversial, the clinical course of this patient suggests that ASCT can improve the prognosis in some patients with EATL.

• Authors: Taichi Ikebe, Yasuhiko Miyazaki, Yui Abe, Kuniko Urakami, Eiichi Ohtsuka, Yoshio Saburi, Masuho Saburi, Takeaki Ando, Kazuhiro Kohno, Masao Ogata, Junichi Kadota
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 49 Issue 19 Pg. 2157-61 ( 2010) ISSN: 1349-7235 [Electronic] Japan
• PMID: 20930447 (Publication Type: Case Reports, Journal Article)

Chemical References

• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisolone

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Combined Modality Therapy
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage, analogs & derivatives)
• Enteropathy-Associated T-Cell Lymphoma (drug therapy, therapy)
• Female
• Humans
• Jejunal Neoplasms (drug therapy, therapy)
• Peripheral Blood Stem Cell Transplantation
• Prednisolone (administration & dosage)
• Remission Induction
• Transplantation, Autologous
• Vincristine (administration & dosage)